Podcasts about Memorial Sloan Kettering Cancer Center

Dr Geoffrey Y Ku from the Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Zev Wainberg from the UCLA School of Medicine discuss patient cases and summarize current treatment approaches for gastroesophageal cancer. CME information and select publications here.

Dr Geoffrey Y Ku from the Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Zev Wainberg from the UCLA School of Medicine discuss patient cases and summarize current treatment approaches for gastroesophageal cancer. CME information and select publications here.

When your doctor says you need “cancer treatment,” do you know what that actually means?Most people immediately think of chemotherapy. But if you or someone you love is facing a cancer diagnosis, understanding the full range of treatment options could be the difference between feeling overwhelmed and feeling empowered.Dr. Katie Deming sits down with Dr. Jason Konner, a medical oncologist at Memorial Sloan Kettering Cancer Center, to break down the three main types of systemic cancer treatment used today: chemotherapy, targeted therapies, and immunotherapies.Chapters:03:43 – Three Main Types of Cancer Treatment16:34 – Why First-Line Therapies Matter20:48 – Combining Holistic and Conventional Care31:23 – Essential Questions to Ask Your Oncologist43:42 – When and Why to Seek a Second OpinionDr. Konnor shares the insider perspective on second opinions, what those complex drug names really mean, and how to build the kind of relationship with your medical team that leads to better outcomes.You'll learn how some patients unknowingly sabotage their own care and what questions can instantly make you a more informed patient. Listen and learn how to walk into any oncologist's office with confidence, ask the right questions, and truly understand your options.Don't let medical jargon and complex choices keep you in the dark when clear thinking matters most.Reserve Your Spot for the June PSYCH-K® Online Workshop: https://www.katiedeming.com/psych-k-june-2025 Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatieMORE FROM KATIE DEMING M.D. Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/ Work with Dr. Katie: www.katiedeming.comEmail: INFO@KATIEDEMING.COM 6 Pillars of Healing Cancer Workshop Series - Click Here to Enroll Follow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER: The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.

In today's episode, supported by Shorla Oncology, we had the pleasure of speaking with Kate Gasparini, PharmD, BCOP, BCPPS, about the use of the oral formulation of imatinib (Imkeldi) for pediatric and adult patients with select leukemias and other malignancies. Gasparini is a pediatric oncology clinical pharmacy specialist at Memorial Sloan Kettering Cancer Center in New York, New York. In our exclusive interview, Gasparini discussed her role as a clinical pharmacy specialist in pediatric oncology, emphasizing her work in patient care, medication reviews, and supportive care. She also noted challenges in administering treatments to patients with dysphagia and emphasized the need for liquid formulations of common therapies. She explained the significance of the availability of the liquid formulation of imatinib, sharing its benefits for patients who struggle with swallowing. Gasparini also addressed potential barriers to accessing this medication, such as insurance coverage limitations, as well as the importance of considering the volume and palatability of liquid formulations to avoid adverse effects and ensure treatment adherence.

This episode is hosted by Emma Keel, MS, CGC, and features Ying Liu, MD, MPH, a Gynecologic Medical Oncologist & Clinical Geneticist, Memorial Sloan Kettering Cancer Center, and Nicole D. Edison, MD, Clinical Associate of Obstetrics & Gynecology, University of Chicago.The in-depth discussion focuses on managing gynecologic cancer risk in patients with Lynch syndrome, spotlighting the significant updates to the National Comprehensive Cancer Network (NCCN) guidelines released in September 2024 that have shifted the clinical approach for these patients. 

Dr. Comen has dedicated her medical career to saving the lives of women. An award-winning, internationally sought-after clinician and physician-scientist, Dr. Comen works as a medical oncologist with a specialty in breast cancer at Memorial Sloan Kettering Cancer Center and is an assistant professor of medicine at Weill Cornell Medical College. She earned her BA in the history of science from Harvard College and her MD from Harvard Medical School, then completed her residency in Internal Medicine at Mount Sinai Hospital and her fellowship in oncology at Memorial Sloan Kettering Cancer Center. She's the author of All In Her Head: The Truth and Lies Early Medicine Taught Us About Women's Bodies and Why It Matters Today which we discuss on the show today. Join The Newsletter + Receive Your Free List of 52 Selfcare Tips Connect with Michele on Instagram RESOURCES MENTIONED Website: https://www.drelizabethcomen.com/ Instagram: https://www.instagram.com/drelizabethcomen/ Book: All In Her Head: The Truth and Lies Early Medicine Taught Us About Women's Bodies and Why It Matters Today If you enjoyed this interview, please take a moment to rate and review it on Apple podcasts. Your reviews are so appreciated! Not sure how to do it? Instructions are below. XO, Michele Rate + Review: 1. Click on this link 2. Click “View in Apple Podcasts” button 3. Make sure to “Follow” 4. Scroll down until you see “Ratings and Reviews” as shown below.

Julian Adams tried but didn't succeed at retirement after a productive career as a medical chemist with several U.S. Food and Drug Association approvals of cancer-related treatments, including cell therapy for bone marrow transplantation. Soon after, his participation in a Stand Up To Cancer advisory group led to his appointment as the nonprofit's president and CEO. The research organization raises money to advance the diagnosis of numerous cancers. Given rapid technological advancements, our podcast hosts were eager to invite Julian on the show to share how Stand Up To Cancer uses artificial intelligence to aid in this pursuit. Read the episode transcript here. For more information on Stand Up To Cancer and how to donate to the organization, please visit this website. Guest bio Julian Adams, president and CEO of Stand Up To Cancer, is among the world's foremost oncology researchers. He was previously CEO of biopharmaceutical company Gamida Cell and president of R&D at Infinity Pharmaceuticals, where he oversaw development of small molecule drugs to treat cancer. He has also held roles at Millennium Pharmaceuticals, Boehringer Ingelheim, LeukoSite, and ProScript. Adams's recognitions include the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, an anti-cancer drug; the 2012 C. Chester Stock Award Lectureship from Memorial Sloan Kettering Cancer Center; and the 2001 Ribbon of Hope Award for Velcade from the International Myeloma Foundation. He holds more than 40 patents and has authored more than 130 papers and book chapters. He received his bachelor's degree and an honorary doctor of science degree from McGill University and his Ph.D. from MIT in synthetic organic chemistry. Me, Myself, and AI is a collaborative podcast from MIT Sloan Management Review and Boston Consulting Group and is hosted by Sam Ransbotham and Shervin Khodabandeh. Our engineer is David Lishansky, and the executive producer is Allison Ryder. Stay in touch with us by joining our LinkedIn group, AI for Leaders at mitsmr.com/AIforLeaders or by following Me, Myself, and AI on LinkedIn. We encourage you to rate and review our show. Your comments may be used in Me, Myself, and AI materials.

On today's show we're excited to welcome Rick Peng, the Innovation Hub Manager and Digital Licensing Professional at Memorial Sloan Kettering Cancer Center. We talk about how your organization can build an outside-in, external innovation program to deliver outsized results. Rick breaks down the secret sauce of the MSK Innovation Hub, an accelerator program designed to encourage collaborations between Memorial Sloan Kettering Cancer Center and digital health companies, focused on the diagnosis, treatment, and care of cancer patients. We discuss their new Innovation Hub Challenge focused on AI Drug Discovery – and why the access to data sets, is a key unlock for ai driven solutions.

This week, Nick Kroll returns to the podcast to discuss the first season of Adults, the last season of Big Mouth and a movie that Mike cannot seem to remember the name of (I Don't Understand You). Nick and Mike delve into the behind-the-scenes realities of Hollywood writer's rooms, development deals, and who Nick is jealous of. Plus, the thing Nick will always regret saying to Robert DeNiro.Please consider donating to: Memorial Sloan Kettering Cancer Center

This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, discusses the evolving treatment landscape for relapsed/refractory diffuse large B-cell lymphoma, focusing on the combination of tafasitamab and lenalidomide. He highlights how this immunotherapy regimen, targeting CD19, has shown promising efficacy, with a high overall response rate and sustained complete responses in some patients. Salles also addresses real-world data, the regimen's tolerability, and its positioning in the treatment sequence, particularly for patients who are not candidates for CAR T-cell therapy. Lastly, he emphasizes the importance of tailoring treatment strategies based on patient characteristics and emerging therapies. Hosted on Acast. See acast.com/privacy for more information.

Parkinson's is a disease that afflicts an estimated 90,000 Americans every year. Current treatment focuses on managing its many symptoms as there is no cure. But a new stem cell-based therapy that creates nerve cells is showing early promise. What's behind this incredible discovery and just how hopeful should patients be? Two of the doctors leading this development, Dr. Lorenz Studer and Dr. Viviane Tabar of Memorial Sloan Kettering Cancer Center, join The Excerpt to share the journey behind this exciting new development.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Shining a light on the caregiving journey for lung cancer patients, Dr. Allison Applebaum, founder of the Caregiver's Clinic at Memorial Sloan Kettering Cancer Center, and caregiver Gail Fackler, along with her husband, Jim, speak candidly about the mental health challenges caregivers face, including anxiety, depression, and PTSD. The conversation covers the overwhelming realities of caregiving, from managing medical decisions to coping with guilt and loss of identity. Gail and Jim share raw, honest stories about how caregiving has transformed their lives and relationships. Practical strategies for caregivers—such as task management, setting boundaries, and finding support networks—offer hope and guidance. Learn more about the  critical importance of mental health support for caregivers and the power of community in navigating this journey. Guests Dr. Allison Applebaum, Founding Director, Caregiver's Clinic, Memorial Sloan Kettering Cancer Center Gail and Jim Fackler, Lung Cancer Caregivers and Patient   Show Notes | Transcript | Watch Video

Ahead of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with a variety of oncology experts about the late-breaking abstracts, plenary sessions, and other key presentations that may shift the paradigm across different cancer care fields. They highlighted anticipated clinical trial results that may transform the standard of care for gynecologic malignancies, lung cancer, and other disease types. Rachel N. Grisham, MD, section head of Ovarian Cancer and director of Gynecologic Medical Oncology at MSK Westchester of Memorial Sloan Kettering Cancer Center, shared her anticipation of findings from the phase 3 ROSELLA trial (NCT05257408) assessing relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer. She stated she was excited to see if the data may represent a new opportunity for this patient population. Next, MinhTri Nguyen, MD, a medical oncologist and hematologist at Stanford Health Care, highlighted a few breast cancer presentations to look out for. These topics included a plenary session on data from the phase 3 SERENA-6 study (NCT04964934) evaluating camizestrant in combination with CDK4/6 inhibitors for those with hormone receptor–positive, HER2-negative advanced breast cancer harboring emergent ESR1 mutations. Additionally, Eric K. Singhi, MD, assistant professor in the Department of General Oncology in the Division of Cancer Medicine, and assistant professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, spoke about a range of potentially practice-changing results in the lung cancer field. For example, he described a session focused on primary results of the phase 3 IMforte trial (NCT05091567) assessing lurbinectedin (Zepzelca) plus atezolizumab (Tecentriq) for those with extensive-stage small cell lung cancer (ES-SCLC). According to Singhi, data from IMforte may shift the paradigm of maintenance therapy for this SCLC population. In the world of head and neck cancer, Douglas R. Adkins, MD, associate professor of Internal Medicine, Division of Oncology, Section of Medical Oncology at Washington University School of Medicine in St. Louis, Missouri, highlighted the session on the phase 3 NIVOPOSTOP GORTEC 2018-01 trial (NCT03576417). Investigators of this study evaluated nivolumab (Opdivo) in combination with chemoradiotherapy for those with resected head and neck squamous cell carcinoma. Adkins noted his excitement to see how these data may impact the standard of care, particularly for patients in Europe, where investigators conducted the study. As part of an Oncology Decoded discussion, Benjamin Garmezy, MD, the associate director of genitourinary research and executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist at SCRI Oncology Partners specializing in genitourinary cancers, discussed key abstracts in bladder cancer. One specific presentation included additional findings from the phase 3 NIAGARA trial (NCT03732677), which may show how circulating tumor DNA can influence treatment decision-making regarding perioperative durvalumab (Imfinzi) for patients with muscle-invasive bladder cancer.

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Evan Matros, MD, discuss the following articles from the May 2025 issue: “Computer-Aided Design and Manufacturing in Free Fibula Reconstruction of the Mandible: Comparison of Long-Term Outcomes with the Conventional Technique” by Bengur, Humar, Saadoun, et al.  Read the article for FREE: https://bit.ly/CADCAMRecon Special guest, Evan Matros, MD is an attending surgeon, Vice Chair of Health Information Technology in the Department of Surgery, and the program director of the microsurgery fellowship at the Memorial Sloan Kettering Cancer Center in New York City. He completed his General Surgery and Plastic Surgery Residencies at Harvard Medical School followed by a microsurgery fellowship at Memorial Sloan Kettering Cancer Center. He also has received his MPH at Columbia University and Master of Medical Science degree from Harvard Medical School. Among his many accomplishments, Dr. Matros is the current vice president of the American Society for Reconstructive Microsurgery Council, he currently serves on the editorial board of the PRS Journal, and he is widely published in reconstructive microsurgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMay25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS

In today's episode, supported by Azurity Pharmaceuticals, we spoke with Michael J. Mauro, MD, about treatment adherence with nilotinib (Tasigna/Danziten) in patients with Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML). Dr Mauro is an attending physician at Memorial Sloan Kettering Cancer Center in New York, New York. In our exclusive interview, Dr Mauro discussed barriers to nilotinib treatment adherence in patients with Ph-positive CML, ways that nonadherence can diminish quality of life and clinical response to treatment, ways that the new formulation of nilotinib addresses adherence issues by reducing the need for fasting, and ongoing research into alternative formulations of other agents that may further improve CML treatment efficacy and tolerability.

In this episode of ASTCT Talks, Dr. Shernan Holtan welcomes Andrew Lin, Manager of Clinical Pharmacy Services of Adult BMT and CTS at Memorial Sloan Kettering Cancer Center, to discuss the evolving role of tacrolimus levels in GVHD prophylaxis within the post-transplant cyclophosphamide (PTCy) era. They explore findings from a recent retrospective study examining whether higher tacrolimus levels offer added protection against GVHD, what this means for toxicity and patient outcomes and how these insights are shaping dosing strategies. The conversation also looks ahead to future research areas, including MMF optimization and the potential for simplified, patient-centered prophylaxis regimens.

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Evan Matros, MD, discuss the following articles from the May 2025 issue: “Legislative Impact and Persistent Disparities: Postmastectomy Breast Reconstruction Rates in the United States among 224,506 Patients” by Schafer, Ho, Potoczak, et al. Read the article for FREE: https://bit.ly/LegislativeReconRate Special guest, Evan Matros, MD is an attending surgeon, Vice Chair of Health Information Technology in the Department of Surgery, and the program director of the microsurgery fellowship at the Memorial Sloan Kettering Cancer Center in New York City. He completed his General Surgery and Plastic Surgery Residencies at Harvard Medical School followed by a microsurgery fellowship at Memorial Sloan Kettering Cancer Center. He also has received his MPH at Columbia University and Master of Medical Science degree from Harvard Medical School. Among his many accomplishments, Dr. Matros is the current vice president of the American Society for Reconstructive Microsurgery Council, he currently serves on the editorial board of the PRS Journal, and he is widely published in reconstructive microsurgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMay25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS

Cancer is among the most common and feared diseases in the modern world. Dr. Selwyn Vickers—president and CEO of Memorial Sloan Kettering Cancer Center—joins host Mark Labberton to discuss how precision oncology, data, and faith are transforming cancer treatment. A distinguished cancer surgeon and pancreatic cancer researcher, Vickers explains how groundbreaking advances in genomics, immunotherapy, and AI are transforming once-lethal diagnoses into survivable and even chronic conditions. Together, they explore not only the cutting-edge science of cancer care but also the spiritual, emotional, and social dimensions that affect every patient and caregiver. Resonating with themes of suffering, hope, and resurrection, this conversation offers clarity, compassion, and courage for all who are affected by cancer—from those newly diagnosed, to medical professionals, to grieving families and curious listeners. Episode Highlights “We're getting to a point where we will, in the next five to seven years, have a much better chance to cure people—and to make pancreatic cancer a chronic illness.” “We are in what's somewhat coined the golden age of cancer research.” “Cancer is a disease that creates an existential threat in ways no other illness does.” “If a tumour forms, it means your body's immune system has made a social contract with the cancer.” “We changed the diagnosis in 10–12 percent of the patients who come to us—sometimes from cancer to no cancer.” “Cancer care is a team sport. And our patients often inspire us more than we help them.” Helpful Links & Resources Memorial Sloan Kettering Cancer Center BioNTech – creators of mRNA vaccines for COVID and cancer CAR T-Cell Therapy Overview (Cancer.gov) Tim Keller on cancer and hope Emma Thompson's Wit (HBO) BRCA1 and BRCA2 Genes and Cancer Risk MSK-IMPACT: Next-Gen Tumor Profiling About Selwyn Vickers Selwyn M. Vickers, MD, FACS, is the president and CEO of Memorial Sloan Kettering Cancer Center (MSK) and the incumbent of the Douglas A. Warner III Chair. He assumed the role on September 19, 2022. Vickers is an internationally recognized pancreatic cancer surgeon, pancreatic cancer researcher, and pioneer in health disparities research. He is a member of the National Academy of Medicine and the Johns Hopkins Society of Scholars. He has served on the Johns Hopkins School of Medicine Board of Trustees and the Johns Hopkins University Board of Trustees. Additionally, he has served as president of the Society for Surgery of the Alimentary Tract and the Southern Surgical Association. Vickers is the immediate past president of the American Surgical Association. He also continues to see patients. In 1994, he joined the faculty of the University of Alabama at Birmingham (UAB) as an assistant professor in the Department of Surgery, where he was later appointed to professor and the John H. Blue Chair of General Surgery. In 2006, Vickers left UAB to become the Jay Phillips Professor and Chair of the Department of Surgery at the University of Minnesota Medical School. Born in Demopolis, Alabama, Vickers grew up in Tuscaloosa and Huntsville. He earned baccalaureate and medical degrees and completed his surgical training (including a chief residency and surgical oncology fellowship) at the Johns Hopkins University. Vickers completed two postgraduate research fellowships with the National Institutes of Health and international surgical training at John Radcliffe Hospital of Oxford University, England. Vickers and his wife, Janice, who is also from Alabama, have been married since 1988. They have four children. Show Notes The ongoing threat and fear of cancer How Selwyn Vickers got into medicine Pancreatic cancer: Vickers's expertise “We are in what's somewhat coined the golden age of cancer research.” Sequencing the human genome “Is there a drug that might target the mutation that ended up creating your cancer?” Cancer as both a medical and existential diagnosis The revolution of precision oncology through human genome sequencing ”It takes a billion cells to have a one centimetre tumor.” Immunotherapy: checkpoint inhibition, CAR T-cell therapy, and vaccines Cellular therapy:   ”Taking a set of their normal cells and re-engineering them to actually go back and target and attack their tumors. … We've seen patients who had initially a 30 percent chance of survival converted to an 80 percent chance of survival.” “We know in many tumours there's something called minimal residual disease.” “Immunizing yourself against cancer is a significant future opportunity.” Managing the power of data with AI and computational oncology Cancer-care data explosion: the role of computational oncologists Cancer vaccines: breakthrough mRNA treatment for pancreatic cancer ”Didn't ultimately win. We had to suffer through her losing her life, but was so appreciative that she got much more than the six months she was promised.” Tumour misdiagnoses and the importance of specialized expertise Pancreatic cancer challenges: immune cloaking and late-stage detection In the past, one in four would die from the operation for removing pancreatic cancer Long-term survival Future of cancer detection: AI-based medical record analysis and blood biopsies More accurate blood tests to confirm conditions Using AI to select those who are high-risk for cancer Pastor Tim Keller died of pancreatic cancer. In the past, “your doctor … helped you learn how to die.” ”[God's] given man the privilege to discover those things that have been hidden. And over time we've gradually uncovered huge opportunities to impact people's lives.” The state of breast cancer research and treatment “If you get the diagnosis of breast cancer, you have a 90 percent chance to survive and beat it over a five-year period of time.” ”In general, we're in a great state of understanding how to treat breast cancer, how to detect it early, and then have selective and targeted mechanisms to prevent it from coming back.” Prostate cancer research and treatment Theranostics: using a specific antibody to target cancer cells specifically Pediatric cancer:  ”We actually treat more children for cancer than any hospital in America now, but in general, the survival for pediatric cancers is greater than 80 percent.” Emotional, psychological, and spiritual toll of cancer: importance of psycho-oncology How Sloan Kettering developed psycho-oncology to help cancer patients with mental and spiritual health Personal story: how a cafeteria worker empowers patients through food choices “We give back to them the right to choose what they get to have on their tray.” Cancer treatment is a team sport. Wit (film, Broadway play)—actress Emma Thompson plays a cancer patient studying the work of John Donne on death Socioeconomic and racial disparities in cancer care outcomes The healing role of community, support teams, and compassionate listening The importance of listening to cancer patients who are preparing to die The spiritual courage of patients and the transformative power of faith “Our patients often help us. We see the grace with which they often handle that journey.” The inspiration behind becoming a doctor: family legacy and human impact Terminal care: the sacred responsibility of walking with patients to the end Cancer research and treatment as a Christian vocation and expression of humanity Production Credits

In today's episode, supported by Revolution Medicines, we spoke with Kathryn C. Arbour, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center in New York, New York, about 2 important abstracts presented at the 2024 AACR Annual Meeting that explore novel RAS-targeted approaches in non–small cell lung cancer (NSCLC). Our discussion focused on early clinical findings with zoldonrasib (RMC-9805) and daraxonrasib (RMC-6236), both of which are RAS(ON) inhibitors under investigation for the treatment of patients with RAS-mutant NSCLC. Zoldonrasib, a KRAS G12D-selective tri-complex inhibitor, was evaluated in a phase 1 trial (NCT06040541) in patients with previously treated, advanced KRAS G12D–mutated solid tumors, including NSCLC. Daraxonrasib, a multi-selective RAS(ON) inhibitor, was highlighted in another phase 1 trial (NCT05379985) in patients with advanced RAS-mutant tumors, including previously treated NSCLC; notably, this AACR presentation focused on the association between early on-treatment circulating tumor DNA level reduction and clinical response with the agent. In this episode, Dr Arbour shared insights into the mechanisms of action behind these therapies, their respective clinical trial designs, and the potential implications that early data with the agents may have for the evolving RAS-mutant NSCLC treatment paradigm.

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Evan Matros, MD, discuss the following articles from the May 2025 issue: “The Financial Impact of a Cosurgeon in Breast Microsurgery” by DeVito, Ke, Park, et al. Read the article for FREE: https://bit.ly/CosurgeonFinance Special guest, Evan Matros, MD is an attending surgeon, Vice Chair of Health Information Technology in the Department of Surgery, and the program director of the microsurgery fellowship at the Memorial Sloan Kettering Cancer Center in New York City. He completed his General Surgery and Plastic Surgery Residencies at Harvard Medical School followed by a microsurgery fellowship at Memorial Sloan Kettering Cancer Center. He also has received his MPH at Columbia University and Master of Medical Science degree from Harvard Medical School. Among his many accomplishments, Dr. Matros is the current vice president of the American Society for Reconstructive Microsurgery Council, he currently serves on the editorial board of the PRS Journal, and he is widely published in reconstructive microsurgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMay25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS

Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/How would your life transform during a 30-day water fast?Dr. Katie Deming is joined by her client Donna DiPane and medical oncologist Dr. Jason Konner from Memorial Sloan Kettering Cancer Center to share an extraordinary healing journey. Donna recently completed a 30-day supervised water-only fast as part of her holistic approach to healing from ovarian cancer. What makes this story especially powerful is the collaborative relationship between conventional and holistic medicine.Chapters:00:17:00 – The fear wasn't just about cancer00:22:00 – I unzipped from my body00:31:00 – A message from God at 3 am00:38:00 – When the shell started to crack00:52:00 – Strip it all down to healThey explore how fasting goes far beyond physical detoxification. Donna shares the profound spiritual awakening she experienced, including receiving powerful messages during the night, connecting with her "light body," and finding a deep release from the fear that had dominated much of her life. Dr. Konner offers his perspective as a conventional oncologist, describing his initial concerns about safety and his surprise at witnessing Donna's transformation throughout the process - not just physically, but emotionally and spiritually.Listen and learn about what happens during a fast, from the physical challenges of the first week to the emotional and spiritual openings that can occur as the body and mind clear.Disclaimer: Never attempt prolonged fasting without proper medical oversight as it can be dangerous. Send us a text with your question (include your phone number)Join Dr. Katie at CANCER: FROM FEAR TO HOPE on May 8, 2025https://heal.regfox.com/heal-from-fear-to-hopeCode: KATIERESILIENCE10 Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatie MORE FROM KATIE DEMING M.D. Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/6 Pillars of Healing Cancer Workshop Series - Click Here to EnrollWork with Dr. Katie: www.katiedeming.comFollow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Take a Deeper Dive into Your Healing Journey: Dr. Katie Deming's Linkedin Here Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER:The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose...

Dr. Fiona Lovely is a longevity, health and wellness expert with specialties in menopause medicine, functional neurology and functional medicine.  She is speaking to the topics of women's health around perimenopause and menopause. In this week's episode, Dr. Lovely sits down with Dr. Shelly Latte-Naor — board-certified internist, integrative medicine physician, and menopause care specialist — for a deeply insightful conversation on supporting menopause for all women and in particular,  in cancer survivors. With a background in mind-body medicine and a former leadership role at Memorial Sloan Kettering Cancer Center, Dr. Latte-Naor brings a wealth of expertise in treating treatment-induced menopause and its often-overlooked effects on women's health post-cancer. Together, they explore how cancer treatments like chemotherapy and hormone blockers can trigger sudden and severe menopausal symptoms, often overlooked in survivorship care. Dr. Latte-Naor breaks down the complexities of hormone therapy in breast cancer patients, including safe uses of local estrogen and emerging research on systemic HRT. The Nitty-Gritty: The hidden toll of cancer treatments: How chemotherapy and hormone blockers can fast-track intense menopause—and why the symptoms are so often dismissed. The truth about hormone therapy in breast cancer survivors: what's safe, what's not, and why the conversation is evolving Non-hormonal solutions for hot flashes, night sweats, and sleep issues—including breakthrough medications and integrative approaches Why sleep disruptions are so common after cancer—and how improving sleep can transform recovery, cognition, and mood The emotional toll of “survivorship shock” and how to rebuild trust in your body after treatment Why self-advocacy is critical—and how to ask for the care you deserve You'll hear about non-hormonal treatment options for:  hot flashes, night sweats, and sleep issues, and how foundational good sleep is to healing and recovery. She also shares powerful insights into the emotional experience of “survivorship shock” and why trauma-informed therapy and self-advocacy are key. If you or someone you know is navigating menopause after cancer (or you're just looking for more ways to support a loved one), this episode is a must-listen. It's a rallying cry for women to demand better care, advocate for themselves, and reframe survivorship as an ongoing journey—one that includes emotional healing, educated choices, and open, honest conversations. You can find more about Dr. Shelly Latte-Naor at shellylattenaormd.com and follow her on Instagram or TikTok. Thank you to our sponsors for this episode:

In this episode of It Takes Balls, Bob Jordan, a Brooklyn-based designer and snowboarder, shares the raw, emotional, and at times unbelievable journey of his testicular cancer diagnosis, treatment, and recovery.What began as a routine backcountry snowboarding trip ended with a bump, a tick bite, and a series of misdiagnoses that nearly cost Bob his life. From fighting for answers to confronting a flawed healthcare system, Bob shares how intuition, persistence, and community helped him survive one of the most challenging periods of his life.He opens up about the trauma of receiving a cancer diagnosis via his patient portal, poor bedside manners, and the gut-wrenching realization that his initial care team missed a critical tumor. After switching to Memorial Sloan Kettering Cancer Center, Bob finally received the expert attention he needed. He also shares what it was like to go through four grueling months of chemotherapy, why he trained his body for treatment, and how a bubble-wrapped snowboard session became a symbol of defiance and hope.But Bob's story doesn't end at remission. He dives into the mental health aftermath, financial strain, and the emotional weight of survivorship, offering an honest look at what it really means to heal. Through creativity, advocacy, and connection, including forming community through Reddit, Bob has turned his experience into a platform for others.Want to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.twitter.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgFollow Steven Crocker: https://www.twitter.com/stevencrockerhttps://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Connect with Bob:https://www.instagram.com/factory808/https://www.808designs.comTheme song: No Time Like Now - Tom Willner www.tomwillner.com

In AARC's latest AARC Perspectives Podcast - Behind the Breath: A Day in the Life of a Cancer Care RT, we are joined by Michelle Rausen, MS, RRT, RRT-NPS, RRT-ACCS of Memorial Sloan Kettering Cancer Center and AARC VP of Membership and Customer Care, Monique Kimmel. Michelle discusses her insights, the emotional and psychological aspects of her work, why RTs in cancer-specific care are so critical, and how AARC is helping to bring the cancer care community together. Additional Resources:AARC Connect Cancer Care CommunityYouTube Live RecordingAbout our guest - Michelle Raussen, MS, RRT, RRT-NPS, RRT-ACCSSend us a textSupport the show

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Evan Matros, MD, discuss the following articles from the May 2025 issue:   “The Financial Impact of a Cosurgeon in Breast Microsurgery” by DeVito, Ke, Park, et al.   “Legislative Impact and Persistent Disparities: Postmastectomy Breast Reconstruction Rates in the United States among 224,506 Patients” by Schafer, Ho, Potoczak, et al.   “Computer-Aided Design and Manufacturing in Free Fibula Reconstruction of the Mandible: Comparison of Long-Term Outcomes with the Conventional Technique” by Bengur, Humar, Saadoun, et al.   Special guest, Evan Matros, MD is an attending surgeon, Vice Chair of Health Information Technology in the Department of Surgery, and the program director of the microsurgery fellowship at the Memorial Sloan Kettering Cancer Center in New York City. He completed his General Surgery and Plastic Surgery Residencies at Harvard Medical School followed by a microsurgery fellowship at Memorial Sloan Kettering Cancer Center. He also has received his MPH at Columbia University and Master of Medical Science degree from Harvard Medical School. Among his many accomplishments, Dr. Matros is the current vice president of the American Society for Reconstructive Microsurgery Council, he currently serves on the editorial board of the PRS Journal, and he is widely published in reconstructive microsurgery.   READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMay25Collection   The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Cohort study evaluated the use of ablative radiation therapy (A-RT) as a noninvasive alternative to surgery in 25 patients with technically resectable pancreatic ductal adenocarcinoma (PDAC) who were ineligible for surgery due to comorbidities. Conducted at Memorial Sloan Kettering Cancer Center between 2016 and 2022, the study found that A-RT, delivered with high precision and dose intensity, provided promising local control and overall survival, with a 2-year OS rate of 43.7% and manageable toxicity. Despite advanced age, poor performance status, and limited chemotherapy use in the cohort, outcomes suggest A-RT may be a viable local therapy for select patients with resectable PDAC, warranting further prospective investigation.Link to Arcticlehttps://jamanetwork.com/journals/jamaoncology/article-abstract/2832566

Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for myelofibrosis. CME information and select publications here.

The International Psycho-Oncology Society (IPOS) deemed April 9th, 2025, the first-ever World Psycho-Oncology Day (WPOD). This day was meant to spread awareness of the importance of prioritizing psychosocial care for patients with all types of cancer as well as to honor Jimmie C. Holland, MD. Prior to WPOD, CancerNetwork® spoke with Cristiane Decat Bergerot, PhD, BS, MS, a psychologist and the head of supportive care at Grupo Oncoclinicas in Brazil, and a member of IPOS, about the importance of psychosocial care and the impact it has on patients with cancer. As stated by Bergerot and listed on the official IPOS website, the primary goals of WPOD are as follows: raise awareness, honor Jimmie Holland, engage stakeholders, promote action, and support fundraising efforts.1 These goals are geared towards paying homage to the history of psycho-oncology and pushing for a more advanced future. “We aim to empower patients, caregivers, and healthcare professionals, fostering a future where psychosocial support is an integral part of oncology worldwide,” Bergerot said.  Psycho-oncology has become more prevalent as a cancer care field since Jimmie C. Holland, MD, worked to help found it in the 1970s. Holland, a “pioneer” of psycho-oncology, was the first ever Chief of Psychiatry Services—a department that was the first of its kind anywhere in the world—at Memorial Sloan Kettering Cancer Center, and a founding member of IPOS.  Bergerot stated that, in her work, she sees that patients who receive psychological support exhibit improved pain management and quality of life. Trials now focus more on end points such as quality of life and patient-reported outcomes, and guidelines have emerged to create standards of care. The National Comprehensive Cancer Network and the American Society of Clinical Oncology each offer guidelines that detail how to manage patient distress as they progress through cancer therapy.2,3 Distress screenings and earlier recommendations for palliative care have also become more standard in treatment.  As for the future, Bergerot highlighted that psychosocial care needs to be more integrated into care as a necessary, rather than optional, component. New developments around the world, however, have created a landscape where telehealth and new research demonstrate the potential to help psycho-oncology grow rapidly.  References 1.        World Psycho-Oncology Day (WPOD). IPOS. Accessed April 2, 2025. https://tinyurl.com/43c9rr2c 2.        Distress during cancer care. NCCN. 2024. Accessed April 2, 2025. https://tinyurl.com/ycxxvnmt 3.        Andersen BL, Lacchetti C, Ashing K, et al. Management of anxiety and depression in adult survivors of cancer: ASCO guideline update. J Clin Oncol. 2023;41(18):3426-3453. doi:10.1200/JCO.23.00293

In today's episode, we invited experts from across oncology specialties to discuss the long-term effects of the COVID-19 pandemic—the onset of which occurred 5 years ago. Our guests shared how the pandemic's lingering effects continue to shape patient care. We heard from:  Ramez N. Eskander, MD, a gynecologic oncologist and assistant professor of obstetrics, gynecology, and reproductive sciences at the University of California San Diego Health Rachel N. Grisham, MD, an associate attending physician at Memorial Sloan Kettering Cancer Center in New York, New York Benjamin Herzberg, MD, an assistant professor of medicine at Columbia University Medical Center and an oncologist at Herbert Irving Comprehensive Cancer Center in New York, New York  Kelly McCann, MD, PhD, an assistant professor and breast medical oncologist at UCLA Health's David Geffen School of Medicine in Los Angeles, California Gregory Roloff, MD, a hematologist/oncologist at the University of Chicago Medicine in Illinois

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

So You've Been Diagnosed With Cancer: Now What? That “now what” is the big question everyone faces when they hear those dreaded worlds: You have cancer. Tune into this episode to hear some helpful advice from Heather's “chief of staff” (aka one of the best friends) Amy Dieterich, and Dr. Starr Mautner, a Board-certified surgeon with clinical expertise in breast surgical oncology of the Breast Center at Miami Cancer Institute, a part of Baptist Health South Florida. Bio: Starr Mautner, M.D., F.A.C.S. Dr. Mautner is a board-certified breast surgical oncologist at the Miami Cancer Institute (MCI) in Miami, Florida. She specializes in performing breast surgical procedures for women with breast cancer, high risk lesions, or women with a genetic predisposition to breast cancer. She grew up in South Florida and earned her undergraduate and medical school degrees as part of the University of Miami's 7-year Medical Scholars Program. She then completed her general surgery residency at Weill Cornell's New York Presbyterian Hospital and clinical fellowship in breast surgical oncology at Memorial Sloan Kettering Cancer Center before moving back to Miami to join the Miami Cancer Institute in 2015. She is the co-chair of the Memorial Sloan Kettering Alliance Education Committee and is very involved in community engagement and educational programs in South Florida. She is also the lead physician for breast surgical oncology clinical trials at MCI and a member of the Breast Cancer Alliance Medical Advisory Board. In her free time, she enjoys spending time with her husband and children exploring Miami or traveling on adventures around the world together. Bio: A dedicated philanthropist with a deep passion for supporting families and children, Amy Dieterich is committed to making a meaningful impact in healthcare and advocacy. As a member of the Chairman's Circle at NYU Hospital and the Children's Advisory Council of New York-Presbyterian Komansky Center for Children's Health, she plays a vital role in shaping initiatives that enhance pediatric care. Her leadership extends to Breakthrough T1D, where she has spearheaded giving campaigns and initiatives to advance research and support for those affected by Type 1 Diabetes. Beyond her philanthropic efforts, she is a strong advocate for women, fostering connections and uplifting women in business. A devoted mom of four boys, she embraces adventure and cherishes traveling with her family, always seeking new experiences and meaningful ways to give back. Find Yonni & Heather here https://www.herhealthcompass.com/

Dr. Sue Yom, Editor in Chief, co-hosts with Dr. Lachlan McDowell, Consultant Radiation Oncologist at the Princess Alexandra Hospital in Queensland, Australia and our journal's Head and Neck Cancer Section Editor. Guests are Dr. Sean McBride, Radiation Oncologist at Memorial Sloan Kettering Cancer Center and Chief of External Beam Radiotherapy at the Manhattan site, who authored an editorial, Oligometastatic HNSCC: Is SABR the Solution?, and Dr. Juliette Thariat, Professor in Radiation Oncology at Cancer Center Baclesse in Normandy, France, Secrétaire Nationale at the GORTEC, and first author of our featured article, Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR.

Dr Kevin S Hughes from the Medical University of South Carolina in Charleston and Dr Mark Robson from Memorial Sloan Kettering Cancer Center in New York discuss current BRCA1/2 genetic testing practices and the clinical management of localized breast cancer with alterations in these genes. CME information and select publications here.

March marks Multiple Myeloma Awareness Month, a crucial time to highlight advances in the treatment of this complex blood cancer. Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Dr. Hamza Hashmi, Assistant Attending in the Myeloma & Cell Therapy Service at Memorial Sloan Kettering Cancer Center, is currently serving as chair of i3 Health CME/NCPD activity, Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma. In this interview, Dr. Hashmi shares additional insights into the evolving role of transplantation in this disease and the importance of education and advocacy during Multiple Myeloma Awareness Month. Click the link for the full activity! https://bit.ly/4hyVwLn

Dermatologic toxicities associated with oncology treatment can significantly impact quality of life and treatment adherence for patients with breast cancer. The Association of Cancer Care Centers (ACCC) is committed to providing up-to-date guidance on managing these dermatologic side effects to enhance clinical outcomes. In this episode of CANCER BUZZ, Allison Gordon, MD, a supportive oncodermatologist at Memorial Sloan Kettering Cancer Center, discusses the dermatologic toxicities associated with breast cancer treatment. Dr Gordon explores preventive measures that oncologists can implement early in the treatment course and offers alternative resources for oncology clinicians when an oncodermatologist referral is not feasible. Additionally, she highlights capivasertib, a recently approved antineoplastic drug, and reviews its associated cutaneous adverse events, along with supportive care and management strategies. Thank you to AstraZeneca for their support of this program.   Allison Gordon, MD Dermatologist Memorial Sloan Kettering Cancer Center New York, NY   “Because many of these medications can cause dry skin, which can be debilitating for patients... [we recommend] using a thick ointment or cream moisturizer on their damp skin after they shower... it doesn't have to be anything expensive... I always recommend that to all patients regardless of what treatment they're on.”– Allison Gordon, MD    Additional Reading/Sources  ACCC Supportive Care Strategies for Dermatologic Toxicities Related to Cancer Therapies education program (https://www.accc-cancer.org/home/learn/comprehensive-cancer-care-services/dermatologic-toxicities?)   Targeted Therapy Side Effects – American Cancer Society  (https://www.cancer.org/cancer/managing-cancer/treatment-types/targeted-therapy/side-effects.html)   Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569770/)   Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy (https://ascopubs.org/doi/10.1200/EDBK_289911)   Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatolgy Study Group (https://mascc.org/resources/mascc-guidelines/)   Guidelines for the Prevention and Treatment of Radiation-Induced Skin Reactions (https://mascc.org/resources/mascc-guidelines/)   Guidelines for Prevention and Management of Dermatological Toxicities Related to Anticancer Agents (https://pubmed.ncbi.nlm.nih.gov/33248228/)

Dr Kevin S Hughes from the Medical University of South Carolina in Charleston and Dr Mark Robson from Memorial Sloan Kettering Cancer Center in New York discuss current BRCA1/2 genetic testing practices and the clinical management of localized breast cancer with alterations in these genes. CME information and select publications here.

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

This week, we'll delve into a cautionary tale: the "Radium Girls." These women were employed to paint glow in the dark numbers on watch faces and dials in the 1920s and 30s using radium paint. Assured that the paint was safe, the girls were instructed to shape their paintbrushes into sharp points with their own lips. But, turns out, ingesting radioactive radium paint isn't safe at all, and as the women became sick and sicker and died, the companies they worked for chose to gaslight them, refusing to take responsibility all while lining their pockets with profits. But these women fought back, standing up while laying down and their fight set an important precedent we can't afford to forget. Let's fix that. Support the show! Join the Patreon (patreon.com/historyfixpodcast)Buy some merchBuy Me a CoffeeVenmo @Shea-LaFountaineSources: International Atomic Energy Agency "What is Radiation"US Department of Energy "Nuclear Fuel Facts: Uranium"Library of Congress Blogs "Radium Girls: Living Dead Women"Wikipedia "Radium Girls"Memorial Sloan Kettering Cancer Center "Hot Times in 'Radium Hospital'"Mariecurie.org "Marie Curie the scientist"American Physical Society "Henri Becquerel Discovers Radioactivity"Northern Public Radio "Ottawa's 'Radium Girls' At Forefront of Worker Protections"Encyclopedia Britannica "Radium Girls: The Women Who Fought For Their Lives in a Killer Workplace"Shoot me a message!

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

Prof Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.CME information and select publications here.

Prof Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.CME information and select publications here.

As part of the US HUPO sponsored "Philly Express" series highlighting speakers at the upcoming 2025 US HUPO meeting in Philadelphia, Ben and Ben sit down to talk with Dr. Kojo Elenitoba-Johnson, Memorial Sloan Kettering Cancer Center.

In today's episode, supported by Genentech, we had the pleasure of speaking with Komal Jhaveri, MD, FACP, about the clinical use of inavolisib (Itovebi) for patients with hormone receptor (HR)–positive, PIK3CA-mutated, locally advanced or metastatic breast cancer. Dr Jhaveri is section head of the Endocrine Therapy Research Program, clinical director of the Early Drug Development Service, and the Patricia and James Cayne Chair for Junior Faculty at Memorial Sloan Kettering Cancer Center in New York, New York. In our exclusive interview, Dr Jhaveri discussed the importance of having a PI3K inhibitor available for the treatment of patients with HR-positive metastatic breast cancer, advice for managing inavolisib-related adverse effects, and best practices for early biomarker testing in patients with breast cancer.

What if your greatest challenges were actually your most profound teachers?  In this soul-stirring conversation, educator and writer Daphne Gregory-Thomas weaves together the threads of loss, resilience, and transformation through her journey as an innovative educator, cancer survivor, and storyteller. Her narrative illuminates how life's greatest challenges often become our most profound teachers, from early maternal loss to creating groundbreaking educational programs for students with learning differences, and ultimately facing her own mortality through cancer diagnosis and recovery.  Through her raw authenticity and deep wisdom, Daphne reveals how staying open to life's lessons - whether they come from students, strangers on New York City streets, or her own healing journey - has shaped her understanding of purpose and meaning. Her story reminds us that every moment holds the potential for transformation if we remain receptive to the teachers who appear in unexpected forms, from classroom students to cancer diagnoses, each offering their unique wisdom for those willing to listen.  Daphne Gregory-Thomas is an essayist and educational innovator who spent 45 years as a high school educator in the New York/New Jersey area, specializing in programs for students with learning differences. After retiring and overcoming two cancer diagnoses, she became a patient-to-patient volunteer at Memorial Sloan Kettering Cancer Center and discovered her voice as a writer through their Visible Ink program. A passionate advocate for authentic living and self-advocacy, Daphne's work focuses on finding wisdom in life's challenges and staying open to unexpected teachers. Her essays explore resilience, transformation, and the power of sharing our stories.  In This Episode:   (00:00) Introduction to Daphne Gregory-Thomas and her background in education (02:16) Early life experiences and learning from her children as teachers (07:38) Creating an innovative program for students with learning differences (09:29) Impact of student's death and continued advocacy (10:41) The inspiring story of student advocacy and transformation (13:05) Impact of the program over 40 years and breaking educational barriers (15:01) Journey through second cancer diagnosis and life-changing decisions (17:37) Finding strength and wisdom from strangers on New York City streets (19:11) Discovering writing through Visible Ink and service as patient volunteer (21:11) Learning from grandchildren and everyday moments, developing intuition and believing in meaningful connections (24:26) Finding balance and gradual transformation Like and subscribe to hear all of our inspirational episodes!  Resources: Daphne Gregory-Thomas LinkedIn  Daphne Gregory-Thomas on Instagram Daphne Gregory-Thomas on Medium Memorial Sloan Kettering Visible Ink writing program  Sign up for Dara's Newsletter Listen to other podcast episodes Here Connect with Dara on Instagram and Facebook Visit DaraLevan.com 

Subscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsIn this episode, Dr. Taz discusses the underappreciated significance of ovarian health with Dr. Piraye Beim, a pioneering biologist and women's health advocate. Dr. Beim reveals startling insights into the ovary as a metabolic, immune, and endocrine organ, and she shares how ovarian function is misaligned with modern human lifespans. The conversation also covers Dr. Beim's revolutionary work in ovarian health and longevity. Dr. Beim also shares practical advice on lifestyle changes to optimize ovarian health and addresses the future of reproductive medicine. Join us in understanding why ovarian health deserves more attention and how it can shape the future of women's health.About Dr. Piraye BeimPiraye Yurttas Beim, PhD is the founder and CEO of Celmatix, a preclinical-stage biotech transforming women's lives through better ovarian health.  With its growing pipeline of innovative drug programs including an AMHR2 agonist program focused on ovarian aging and an oral FSH for infertility, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. Dr. Beim has dedicated herself to innovating in women's health for more than 20 years. During her PhD work at Cornell University (Weill, NYC) and Memorial Sloan Kettering Cancer Center, she was on the front lines of the precision medicine revolution in oncology. She then completed her post-doc at the University of Cambridge (UK), focusing on the science of fertility.Thank you to our sponsorTimeline: timeline.com/DRTAZ06:09 The Role of Ovaries in Human Health12:59 The Impact of Inflammation and Metabolism31:56 Potential Benefits for Women with PCOS37:16 Optimizing Ovarian Health Today40:11 Lifestyle Practices to Support Ovarian Health43:24 The Role of Light and Sleep48:45 Endometriosis and Ovarian Health51:00 Inspiration and Future GoalsStay ConnectedSubscribe to the audio podcast: https://holplus.transistor.fm/subscribeSubscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsFollow Dr. Taz on Instagram: https://www.instagram.com/drtazmd/https://www.instagram.com/liveholplus/Join the conversation on X: https://x.com/@drtazmdTikTok: https://www.tiktok.com/@drtazmdFacebook: https://www.facebook.com/drtazmd/Connect with Dr. Piraye Beim:https://www.instagram.com/boss_ovary/https://bit.ly/m/Boss_OvaryHost & Production TeamHost: Dr. Taz; Produced by Rainbow Creative (Executive Producer: Matthew Jones; Lead Producer: Lauren Feighan; Editors: Jeremiah Schultz and Patrick Edwards)Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+

Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York discusses available data guiding treatment decision-making for patients with newly diagnosed multiple myeloma. CME information and select publications here.

In today's episode, supported by Takeda, we had the pleasure of speaking with Mark B. Geyer, MD, and Elias Jabbour, MD, about updates in the management of Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). Dr Geyer is the Adolescent and Young Adult Program leader and the Adult Lymphoblastic Leukemia Program leader in the Leukemia Service, as well as the chair of Quality Assessment in the Cellular Therapy Service at Memorial Sloan Kettering Cancer Center in New York, New York. Dr Jabbour is a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Drs Geyer and Jabbour discussed the use of ponatinib (Iclusig) in patients with Ph-positive ALL as evidenced by key findings from research such as the pivotal phase 3 PhALLCON trial (NCT03589326). They also highlighted the potential efficacy of this agent in combination with blinatumomab (Blincyto) and shared insights on how the safety profile of this agent affects its clinical use.

Dr Enriqueta Felip from the Vall d'Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. CME information and select publications here